Abstract Objective To study the clinical significance of CD163 in the diagnosis and the evaluation of severity and prognosis of childhood hemophagocytic lymphohistiocytosis (HLH). Methods Ninety-four children were classifieied into Epstein-Barr virus (EBV)-positive (n=55) and EBV-negative groups (n=39; control group). The EBV-positive group was subgrouped into infectious mononucleosis (IM; n=47) and HLH (n=8). Serum levels of soluble CD163 were measured using ELISA. Expression of CD163 on mononuclear cells was detected by flow cytometry. Results The serum levels of soluble CD163 were > 10 000 ng/mL in all eight HLH patients (> 30 000 ng/mL in 3 cases). The mean serum levels of soluble CD163 in the HLH group were significantly higher than in the control and IM groups (P<0.05). The serum levels of soluble CD163 in EBV-positive children were positively correlated with EBV-DNA copies and serum levels of ferritin and LDH, but were negatively correlated with white blood cell count, neutrophil count, hemoglobin and platelet count. The follow-up after treatment for three HLH patients showed that serum levels of soluble CD163 were significantly reduced, but the soluble CD163 levels rebounded in one patient who was complicated by fungal pneumonia infection. Conclusions The levels of serum soluble CD163 may be related to the severity in children with HLH. The EBV-positive children with soluble CD163 levels >10 000 ng/mL should be considered the possibility of HLH.
Filipovich AH. Hemophagocydc lyrephohistiocytosis (HLH) and related disorders[J]. Hematol Am Soc Hematol Educ Program, 2009: 127-131.
[2]
Switala JR, Hendricks M, Davidson A, et al. Serum ferritin is a cost-effective laboratory marker for hemophagocytic lymphohistiocytosis in the developing world[J]. J Pediatr Hematol Oncol, 2012, 34(3): e89-e92.
[3]
Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis[J]. Blood, 2011, 118(15): 4041-4052.
[4]
Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2): 124-131.
Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome[J]. Eur J Haematol, 2005, 74(1): 6-10.
Weaver LK, Pioli PA, Wardwell K, et al. Up-regulation of human monocyte CD163 upon activation of cell surface Toll-like receptors[J]. J Leukoc Biol, 2007, 81(3): 663-671.
[10]
Moniuszko M, Kowal K, Rusak M, et al. Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples: influence of different anticoagulants[J]. Clin Vaccine Immunol, 2006, 13(6): 704-707.
[11]
Onofre G, Kolackova M, Jankovicova K, et al. Scavenger receptor CD163 and its biological functions[J]. Acta Medica (Hradec Kralove), 2009, 52(2): 57-61.
[12]
Nguyen TT, Schwartz EJ, West RB, et al. Expression of CD163 in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage[J]. Am J Surg Pathol, 2005, 29(5): 617-624.
[13]
Kowal K, Silver R, Sławinska E, et al. CD163 and its role in inflammation[J]. Folia Histochem Cytobiol, 2011, 49(3): 365-374.
